1994

Thromboxane Modulates Endothelial Permeability

Klausner, J. M.

Hindawi Publishing Corporation


http://hdl.handle.net/2144/3123

Boston University
This study tests the role of thromboxane in modulating microvascular permeability in vitro. Cultured monolayers of bovine aortic endothelial cells were challenged with the thromboxane (Tx) mimic U46619. This led to disassembly of actin microfilaments, cell rounding, border retraction and interendothelial gap formation. Pretreatment with the Tx receptor antagonist SQ 29,548 prevented the Tx mimic-induced cytoskeletal changes. The Tx mimic also altered endothelial cell barrier function. Increased permeability was indicated by the increased passage of labelled albumin across monolayers cultured on microcarriers, relative to untreated endothelial cells (p < 0.05). Furthermore, electron microscopy of endothelial cells cultured on the basement membrane of human placental amnion indicated increased permeability based on wide, interendothelial gap formation and transit of the tracer horseradish peroxidase. Quantification of interendothelial gaps revealed an eleven-fold increase with the Tx mimic relative to untreated endothelial cells (p < 0.05) and prevention by pretreatment with the Tx receptor antagonist (p < 0.05). These data indicate that Tx directly modulates the permeability of endothelial cells in vitro.

**Key words:** Cytoskeleton, Endothelium, Permeability, Thromboxane

**Introduction**

Thromboxane (TX)A₂, a potent vasoconstrictor agent is thought to be a significant mediator of the respiratory failure noted in a variety of clinical and experimental disorders including those related to ischaemia and reperfusion, endotoxaemia, complement activation, microembolization, aspiration and burns. Since TXA₂ has a 30s half-life, interpretation of its pathophysiological role has been derived from measurement of its relatively stable hydrolysis product, TXB₂, and from effects observed when TX synthesis was blocked pharmacologically. Conclusions drawn from these observations are open to potential error. The presence of increased TXB₂ levels in plasma does not necessarily reflect the involvement of TXA₂ in organ pathology. Further, many TX inhibitors, such as drugs blocking cyclooxygenase are non-selective and may inhibit the synthesis, binding or degradation of other arachidonic acid (AA) metabolites and possibly oxygen free radicals. Even relatively selective inhibitors of TX synthetase may redirect the endoperoxide precursors away from the TXA₂ pathway towards prostaglandin (PG) or leukotriene synthesis. Finally, studies designed to test whether a pathophysiological effect could be induced by infusion of an agonist have also been marred by the use of nonspecific agents such as AA. Infusion of this precursor can result in the production of a variety of cyclooxygenase as well as lipoxygenase products. It is therefore not surprising that conflicting results have been reported regarding the effects of TX on microvascular permeability.

Significant evidence has been obtained indicating that TXA₂ may produce vasoconstriction and bronchospasm and that TX can induce platelet aggregation and leukocyte adhesion. However, given the methodological problems, the role of TX in modulating microvascular increased permeability is less certain. This study was designed to test the putative TX action on the vascular barrier utilizing a stable TX mimic and a TX receptor antagonist.

**Materials and Methods**

*Studies of barrier function.* The effect of the TX mimic on endothelial cell (EC) barrier function was evaluated using the permeability assay originally described by Boiadjieva et al. and modified by Bottaro et al. This technique allows the quantitation of transendothelial solute transport by measuring the movement of tracer dye bound to albumin through a monolayer of endothelial cells grown on microcarrier beads. The movement of the tracer dye from the medium to the bead matrix is followed spectrophotometrically.

Bovine aortic EC were obtained as described previously. Endothelial cells were identified by
their characteristic growth morphology, colony pattern and presence of factor VIII antigen.\textsuperscript{8,11} Primary cultures were subcultured a maximum of two times before seeding onto Cytodex 3 microcarrier beads (Pharmacia, Inc., Piscataway, NJ). Microcarriers were kept in suspension using a Techne MCS-104S magnetic stirrer (Techne Inc., Needham, MA) operated at 44 rpm inside a conventional tissue culture incubator. Endothelial cells were seeded onto the microcarriers at a minimum density of 10 cells per bead, and allowed to grow for at least 6 days post-confluency.

Tryplan blue (TB) dye (Fisher Scientific, Pittsburg, PA) and bovine serum albumin (BSA) (Sigma, St. Louis, MO) were added to DMEM so that the final concentrations of TB and BSA were 0.2\% and 0.45\% respectively. The molecular weight of this TB–BSA complex was 100 000.\textsuperscript{8} Five ml samples of microcarrier suspension, with a concentration of 40 000 microcarrier beads/ml were placed in a plastic vial. The growth medium was replaced by DMEM plus the TB-BSA dye solution to which the Tx mimic U46619 (9,11-dideoxy-M, 9-epoxymethano-PGE\textsubscript{2}) (Upjohn, Kalamazoo, MI) at 10\textsuperscript{-4} M or 10\textsuperscript{-5} M or the Tx receptor antagonist at 10\textsuperscript{-4} M, or both mimic and antagonist at 10\textsuperscript{-4} M respectively had been added. Five sets of experiments were performed. Non-cell coated microcarriers (naked beads) were included in every experiment to provide a maximum for the rate of TB–BSA uptake into the microcarrier matrix. The vehicles of either Tx mimic or the Tx receptor antagonist SQ 29,548 (Squibb, Princeton, NJ) were also added in two experiments. The vials were placed in a 37\textdegree C water bath and agitated gently. At 5 and 15 min 150 l.t.t. of beads and dye solution were removed from the vials and placed on an oil cushion of dibutyl:dioctylphthalate in a ratio of 3:1. The aliquots were then centrifuged for 30 s at 1500 x g. This effectively separated the microcarriers from the medium and terminated the dye uptake by the microcarrier beads. Dye concentration in the supernatant was then assayed by mixing a 50 btl aliquot of supernatant with 950 btl of distilled water. Absorbance was read at 580 nm with a Beckman DU-50 spectrophotometer. All samples were analysed in triplicate. Results are expressed as the reciprocal of the supernatant absorbance.\textsuperscript{8}

Endothelial cell morphology and cytoskeleton: EC were seeded onto 1.2 cm, 1.5\% gelatin coated coverslips. At 3 days post confluency, cell monolayers were exposed to the Tx mimic or Tx receptor antagonist or their combination in DMEM at concentrations of 10\textsuperscript{-5} M respectively in DMEM for 5 min at 37\textdegree C. After brief rinsing of the EC, the tracer horse-radish peroxidase (HRP) (Sigma) 0.5 mg/ml was added for 10 min at 37\textdegree C. Monolayers were then fixed and processed for HRP localization.\textsuperscript{13} Thin 90 nm sections were examined on a Phillips 410 electron microscope. Thick 2.5 mm sections were mounted on glass slides and viewed under an in-

![FIG. 1. Dye–albumin concentration in the supernatant varied inversely with the passage of the dye–albumin conjugate across the endothelial cell (EC) monolayer grown on the microcarrier beads. Untreated EC had a measurable barrier and decreased the passage of albumin relative to naked beads. Incubation with the Tx mimic increased the passage of dye labelled albumin across the EC monolayer indicating decreased barrier function. Pretreatment with the Tx receptor antagonist SQ 29,549 prevented the Tx induced increase in permeability. Treatment of untreated EC with the Tx antagonist alone decreased the passage of albumin relative to untreated EC indicating enhanced barrier function. Asterisks refer to significance relative to untreated EC, and daggers indicate significant differences between EC treated with Tx mimic alone and the combination of Tx mimic and antagonist. ](image)

![Absorbance (580 nm) vs Time (min)](chart)

 Untreated  
 Tx mimic 10\textsuperscript{-5} M  
 Tx mimic 10\textsuperscript{-4} M  
 Tx antagonist 10\textsuperscript{-4} M  
 Tx mimic + antagonist 10\textsuperscript{-4} M

150 Mediators of Inflammation Vol 3. 1994
verted Zeiss microscope (x 400). Changes in permeability were assessed by following the passage of HRP through the EC monolayer. In addition, the number of interendothelial leakage sites and enlarged gaps were counted in ten randomly selected microscopic fields.

Results are expressed in the text and figures as mean ± standard error. Differences between means were tested by an analysis of variance, paired and non-paired t-test. When multiple time points were compared the Bonferroni test was applied. Significance was accepted if p < 0.05.

Results

Bovine aortic EC grown to confluence on microcarrier beads formed a measurable barrier to

FIG. 2. Compared to untreated EC (A), in which the actin microfilament elements of the cytoskeleton are apparent, cells incubated for 5 min with Tx mimic at 10⁻⁴ M (B) or at 10⁻³ M (C) showed disassembly of actin microfilaments, border retraction, cell rounding and interendothelial gap formation (x 1150).

the passage of the TB–BSA conjugate into the microcarrier matrix and the amount of TB–BSA taken up by the EC covered microcarriers was significantly less than the amount taken up by 'naked' microcarriers (Fig. 1). Treatment of EC with the Tx mimic at concentrations of 10⁻⁴ M and 10⁻³ M increased TB–BSA passage across the EC into the microcarrier matrix after 5 and 15 min, relative to untreated cells (p < 0.01) (Fig. 1). This effect was more pronounced for the higher concentration of 10⁻³ M. The Tx antagonist SQ 29,548 enhanced the barrier function as indicated by reduced passage of the tracer relative to untreated EC (p < 0.01) (Fig. 1). Incubation of EC with SQ 29,548 10⁻⁴ M for 5 min prior to their exposure to Tx mimic at 10⁻⁴ M prevented the increased TB–BSA passage across the EC induced by Tx mimic alone (Fig. 1). The vehicles of either Tx mimic or SQ 29,548 did not affect barrier function relative to untreated EC (data not shown).

Compared with untreated EC, cells challenged with the Tx mimic for 5 min showed border retraction, cell rounding, disassembly of EC actin microfilaments and interendothelial gap formation (Fig. 2). These changes were not quantified but were more pronounced with Tx mimic at 10⁻³ M compared to a concentration of 10⁻⁴ M. The latter however induced cytoskeletal changes that were apparent relative to untreated EC. Pretreatment with SQ 29,548
The permeability changes required Tx mimic concentrations that were very high compared to other in vitro systems. Nevertheless, the suppression by the Tx receptor antagonist makes a nonspecific effect on endothelial cytoskeleton and permeability rather unlikely.

We believe that Tx acts to moderate microvascular permeability by altering the EC cytoskeleton. Certain cytoskeletal elements, especially actin microfilaments, appear to regulate EC mobility, structural relationship to adjacent cells and therefore interendothelial junctions and barrier function. Agents such as phalloidin promote microfilament assembly, thereby tightening interendothelial junctions and enhancing barrier function. Similar to native TXA₂, the Tx mimic as well as other permeability promoting agents such as histamine, lead to a reversible disassembly of cytoskeletal actin microfilaments, events associated with widening of interendothelial junctions and increased permeability to protein. Despite the uniformity of these observations, in vivo studies by others have failed to demonstrate increased lung permeability with agents such as histamine, arachidonic acid metabolites, and platelet activating factor, despite the ability of these agents to affect EC cytoskeleton in vitro. The application of aortic EC cultures as models of in vivo lung permeability is limited and interpretations must be made cautiously. Our results do not preclude the possibility that Tx may affect aortic EC cytoskeleton and barrier function differently than pulmonary microvessels. In fact, Maron's observation suggests that intrinsic differences in the regulation of microvascular permeability exist between the systemic and pulmonary vasculature; histamine induced increased permeability of canine systemic blood vessels but failed to affect the barrier function in the dog and rabbit lung. However, other studies indicate that histamine as well as other agents, that is leukotrienes, interleukin-1 and interleukin-2 and platelet activating factor, increase the permeability of both the systemic and the pulmonary vasculature. These conflicting results may relate to different methodologies and species. For example, the sheep lung may be especially susceptible to changes in permeability because of its rich population of intravascular macrophages. These cells can respond to a permeability promoting agent by further release of inflammatory mediators that may themselves affect the vascular integrity in the lung. Despite these considerations, aortic EC and pulmonary microvessel EC have been found to be quantitatively comparable with regard to the passage of albumin suggesting that data from aortic EC may be extrapolated to pulmonary EC.

**Discussion**

The chemically stable endoperoxide analogue used in these studies is believed to act as a biological mimic of TXA₂. This is indicated by its ability to constrict smooth muscle and, in higher dosage, to aggregate platelets and increase white blood cell chemotaxis. Further, U46619 and TXA₂ display the same pattern of agonist responses on lung strips and vascular preparations from several species. Finally, the ability of the Tx receptor antagonist to inhibit the effects of native TXA₂ as well as the effects of the mimic indicate identical receptor sites and actions for native TXA₂ and the Tx mimic.
Thromboxane-endothelial permeability

TxA2 can enhance neutrophil endothelial adhesion87 and promote neutrophil diapedesis through EC monolayers.15 The Tx mimic has identical actions on WBC–EC interaction when tested in vitro.15 Further, infusion of the Tx mimic in swine led to neutrophil sequestration in the lungs.28 Activation of these sequestered neutrophils may lead to increased permeability. Although neutrophils may enhance Tx induced permeability they are not necessary for its expression. In other studies oedema has been reported in isolated lungs, free of white blood cells, challenged with nicotine or alphathrombin.30 These agents stimulate Tx synthesis and lead to Tx dependent increases in permeability.

Concentrations of TxB2 are elevated in a number of clinical and experimental settings of increased permeability. This does not document a casual relationship. Thus, the increased plasma Tx concentrations during endotoxaemia are not as important as other mediators of permeability since Tx inhibition is not preventative.54 On the other hand, in other settings Tx appears central in mediating microvascular permeability. For example, inhibition of Tx prevents increased microvascular permeability in the ischaemic reperfused dog hind limb,35 in sheep lungs following microembolization,30 or lower torso ischaemia with reperfusion,35 and in rat lungs challenged with inhaled nicotine.59 In summary, these data suggest that thromboxane A2 directly moderates microvascular permeability in vitro.

References


ACKNOWLEDGEMENTS. This work was supported in part by The National Institute of Health, Grants No. GM24891-10, GM35141-03, HLM07413-15, The U.S. Navy Office of Naval Research, Contract No. N00014-79-C-1068, The Brigham Surgical Group, Inc. and The Trauma Research Foundation.

Received 13 December 1993; accepted in revised form 14 January 1994